FormBlends Video Library

Playlists

Playlist: Tirzepatide

Four videos on the dual GIP and GLP-1 agonist: a journal summary of an off-label study, a specialist journal club, a conversation with a SURPASS investigator, and a head-to-head with semaglutide from a diabetes nonprofit.

1 min readUpdated September 4, 2026By FormBlends editorial team3 sourcesEducational, not medical advice

What this page covers

From the data
What this page covers: 1. Watch order and why; 2. Numbers to carry with you; 3. Where these videos stop.What this page covers: 1. Watch order and why; 2. Numbers to carry with you; 3. Where these videos stop.1Watch order and why2Numbers to carry with you3Where these videos stop
The 3 parts of this page in reading order, taken from its section headings.

Calculator

Playlist player

Open full calculator

Tirzepatide: 4 videos, about 76 minutes in total. Watch in order; each write-up assumes the ones before it.

  1. 1 of 4 · 3:44

    Effect of Tirzepatide on Body Weight & Diabetes Control

    Mayo Proceedings · Original

    Two Mayo Clinic research fellows summarise their Mayo Clinic Proceedings paper: in adults with type 1 diabetes and overweight or obesity treated with tirzepatide, mean weight loss of 8.5 percent at a median 8 months and 12 percent at 12 months, a 1 percentage-point A1c fall and a 31.6 percent drop in insulin requirement.

    Read the full fact-check

  2. 2 of 4 · 48:11

    EFL021 - Metabolic Effects of a Dual GIP and GLP-1 RA

    Endocrine Society · Original

    An Endocrine Society journal club on a JCEM metabolomics analysis of a 26-week phase 2 trial against dulaglutide and placebo: tirzepatide lowered branched-chain amino acids and their catabolites, 2-hydroxybutyrate and several triglyceride and diglyceride species in a dose-dependent way, changes that correlated with insulin-sensitivity markers.

    Read the full fact-check

  3. 3 of 4 · 16:44

    Interpreting the Data with Tirzepatide

    Cardiometabolic Health Congress (CMHC) · Original

    Two clinical trialists discuss tirzepatide as it was in early 2023: SURPASS glycaemic results, SURMOUNT-1 weight loss, the 2.5 mg start and four-week steps, switching from a GLP-1, the oral contraceptive caution in the label and the absence of a cardiovascular outcomes trial at the time.

    Read the full fact-check

  4. 4 of 4 · 7:45

    GLP-1 Showdown: Mounjaro vs. Ozempic - Which one is right for you? | TCOYD

    Taking Control Of Your Diabetes® · Original

    Two endocrinologists from the nonprofit TCOYD compare tirzepatide and semaglutide category by category: A1c and weight favour tirzepatide in SURPASS-2, kidney and heart outcome data favour semaglutide, sleep apnoea favours tirzepatide, and both must be continued to keep the benefit.

    Read the full fact-check

Watch order and why

We put the Mayo Clinic Proceedings video first because it is short and because its fact-check teaches the most important habit for this molecule: check the label before believing a use is established. Tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnoea; the study in that video is off-label and retrospective. The Endocrine Society journal club follows for viewers who want the pharmacology of dual agonism. The CMHC conversation with Dr. Juan Frias is the practical core: dose steps, switching, the contraceptive caution, cardiovascular data as of 2023. TCOYD's comparison closes by placing tirzepatide against semaglutide category by category.

Numbers to carry with you

SURMOUNT-1, 72 weeks, adults without diabetes: mean weight change of 15.0, 19.5 and 20.9 percent on 5, 10 and 15 mg against 3.1 percent on placebo (PubMed 35658024). Label escalation: 2.5 mg for four weeks, then 2.5 mg steps at least four weeks apart to a maximum of 15 mg. Most common adverse reactions in the Zepbound label: nausea 25 to 29 percent, diarrhoea 19 to 23 percent, constipation 11 to 17 percent, vomiting 8 to 13 percent, against single-digit to low-teen placebo rates.

Where these videos stop

None of the four is current on SURPASS-CVOT or SURMOUNT-5, and none discusses compounded tirzepatide, which is not FDA approved and is not interchangeable with Mounjaro or Zepbound. FormBlends dispenses compounded tirzepatide at formblends.com/products/tirzepatide and discloses that interest here. For a dated titration plan, units conversion for vials and the missed-dose rule from the label, use the Tirzepatide Hub. For every SURMOUNT and SURPASS result with confidence intervals, FormBlends Research.

Sources (3)

  1. Zepbound (tirzepatide) prescribing information, DailyMed set id 487cd7e7-434c-4925-99fa-aa80b1cc776b Accessed September 4, 2026.
  2. Mounjaro (tirzepatide) prescribing information, DailyMed set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0 Accessed September 4, 2026.
  3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022. PubMed 35658024 Accessed September 4, 2026.

Canonical URL: https://formblendsvideos.com/playlists/tirzepatide. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.